One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension

To evaluate the maintenance of efficacy and safety of insulin glargine 300 U/ml (Gla‐300) versus glargine 100 U/ml (Gla‐100) in people with type 2 diabetes mellitus (T2DM) using basal plus meal‐time insulin for 12 months in the EDITION 1 trial.

• Publication year

  2015

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2015-05-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/dom.12472PMID 25846721PMCID 4676922
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)

  2015cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 1)

  2014influential reference
• Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

  2014cited by this paper
• New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

  2014cited by this paper
• Will the next generation of basal insulins offer clinical advantages?

  2014cited by this paper
• Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose-response study.

  2014cited by this paper
• New Insulin Glargine 300 Units·mL−1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units·mL−1

  2014cited by this paper
• Evolution of Insulin Development: Focus on Key Parameters

  2012cited by this paper
• The Gains from Delegation Revisited: Price-Level Targeting, Speed-Limit and Interest Rate Smoothing Policies

  2011cited by this paper
• Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era

  2011cited by this paper
• Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003).

  2006cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• When oral agents fail: practical barriers to starting insulin

  2002cited by this paper
• Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation

  1998cited by this paper
• A Measure of Treatment Satisfaction Designed Specifically for People with Insulin‐dependent Diabetes

  1988cited by this paper

• Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study

  2026cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.

  2025cites this paper
• Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials

  2024cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025.

  2024cites this paper
• Efficacy and safety of insulin glargine 300 U/mL in people with type 2 diabetes in China: The INITIATION study

  2024cites this paper
• Clinical impact after implementing an insulin protocol involving a switch to insulin glargine 300 U/ml as basal insulin for inpatient glycaemic control: A retrospective single-centre study.

  2023cites this paper
• Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: A systematic literature review and meta‐analysis

  2023cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024.

  2023cites this paper
• ONWARDS and upwards for basal insulin.

  2023cites this paper
• Abordaje integral de las personas con diabetes tipo 2. Área de Conocimiento de Diabetes de la Sociedad Española de Endocrinología y Nutrición

  2022cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023.

  2022cites this paper
• Efficacy and safety of different basal and prandial insulin analogues for the treatment of type 2 diabetes: a network meta-analysis of randomized controlled trials

  2021cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022.

  2021cites this paper
• Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study

  2021cites this paper
• Insulin glargine 300 U/ml for the treatment of feline diabetes mellitus

  2021cites this paper
• Comparison of Insulin Glargine 300 U/mL versus Glargine 100 U/mL on Glycemic Control and Hypoglycemic Events in East Asian Patients with Type 2 Diabetes: A Patient-level Meta-Analysis of Phase 3 Studies.

  2021cites this paper
• Pharmacologic Approaches to Glycemic Treatment of Type 2 Diabetes: Synopsis of the 2020 American Diabetes Association's Standards of Medical Care in Diabetes Clinical Guideline

  2020cites this paper
• Efficacy and safety of insulin glargine 300 U/mL (Gla-300) during hospitalization and therapy intensification at discharge in patients with insufficiently controlled type 2 diabetes: results of the phase IV COBALTA trial

  2020cites this paper
• Understanding the Clinical Profile of Insulin Degludec, the Latest Basal Insulin Approved for Use in Canada: a Narrative Review

  2020cites this paper
• Changes in fasting patterns during Ramadan, and associated clinical outcomes in adults with type 2 diabetes: A narrative review of epidemiological studies over the last 20 years.

  2020cites this paper
• Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes.

  2020cites this paper
• Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats.

  2020cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021.

  2020cites this paper
• Risk of hypoglycaemia with insulin degludec versus insulin glargine U300 in insulin-treated patients with type 2 diabetes: the randomised, head-to-head CONCLUDE trial

  2020cites this paper
• Special aspects of concentrated insulins: basic characteristics and research findings

  2020cites this paper
• Diabetes mellitus type 2 in adults

  2020cites this paper
• Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study

  2020cites this paper
• Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)

  2019cites this paper
• Titration of insulin glargine 100 U/mL when added to oral antidiabetic drugs in patients with type 2 diabetes: results of the TOP-1 real-world study

  2019cites this paper
• Long-Acting Basal Insulins: A Review of the More Recently Approved Agents.

  2019cites this paper
• A comprehensive approach to type 2 diabetes mellitus – A recommendation document

  2019cites this paper
• Nueva generación de insulinas: glargina U300. Resumen de evidencia clínica.

  2019cites this paper
• Efficacy and safety of insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Asia Pacific insulin‐naïve people with type 2 diabetes: The EDITION AP randomized controlled trial

  2019cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

  2019cites this paper
• Comparative effectiveness and harms of long‐acting insulins for type 1 and type 2 diabetes: A systematic review and meta‐analysis

  2019cites this paper
• Primary Care Management of Patients With Type 2 Diabetes: Overcoming Inertia and Advancing Therapy With the Use of Injectables.

  2019cites this paper
• Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes

  2019cites this paper
• Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.

  2019cites this paper
• Document on a comprehensive approach to type 2 diabetes mellitus.

  2019cites this paper
• Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis

  2019cites this paper
• Reporting of hypoglycaemia in clinical trials of basal insulins: A need for consensus

  2019cites this paper
• Insulintherapie beim Typ-2-Diabetes

  2019cites this paper
• Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.

  2019cites this paper
• Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal.

  2019cites this paper
• Insuline glargine Gla-300 (Toujeo®) : de sa formulation à son utilisation en pratique clinique

  2019cites this paper
• Efficacy and safety of the second generation basal insulin analogs in type 2 diabetes mellitus: A critical appraisal.

  2019cites this paper
• A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient Management of Medicine and Surgery Patients With Type 2 Diabetes: Glargine U300 Hospital Trial

  2019cites this paper
• Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Insulin depot absorption modeling and pharmacokinetic simulation with insulin glargine 300 U/mL

  2018cites this paper
• Möglichkeiten und Grenzen der aktuellen Insulintherapie

  2018cites this paper
• GlucoTab‐guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalized patients with type 2 diabetes

  2018cites this paper
• Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis

  2018cites this paper
• Insulin therapy for type 2 diabetes – are we there yet? The d-Nav® story

  2018cites this paper
• 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019

  2018cites this paper
• Basal–Bolus Insulin Therapy with Gla-300 During Hospitalization Reduces Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Study

  2018cites this paper
• Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.

  2018cites this paper
• Temporary Reductions in Insulin Requirements Are Associated with Hypoglycemia in Type 2 Diabetes

  2018cites this paper
• Comparative Benefits andHarms of Basal Insulin Analogues for Type 2 Diabetes A Systematic Review andNetworkMeta-analysis

  2018cites this paper
• Efficacy, safety and clinical use of newer basal insulins analogs

  2018cites this paper
• Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019

  2018cites this paper
• Type 2 Diabetes Mellitus: Outpatient Insulin Management.

  2018cites this paper
• LOWER DAILY DOSE WITH BETTER OUTCOMES WITH ORAL AGENTS AND AM INSULIN TOUJEO ADMINISTRATION THAN LANTUS WHILE ATTAINING DESIRABLE GLYCEMIC CONTROL IN TYPE 2 DIABETES

  2018influential citation
• Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature

  2018influential citation
• Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.

  2018cites this paper
• Understanding concentrated insulins: a systematic review of randomized controlled trials

  2018cites this paper
• High Concentration Insulin

  2018influential citation
• Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use

  2018cites this paper
• Ultra-long-acting insulins: A review of efficacy, safety, and implications for practice

  2018cites this paper
• Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes

  2018cites this paper
• Continuation of evolution: Headliner glargine U300.

  2018cites this paper
• A comparison of the clinical courses of type 2 diabetic patients whose basal insulin preparation was replaced from insulin glargine 100 units/mL to insulin glargine biosimilar or 300 units/mL: a propensity score-matched observation study

  2018cites this paper
• Improved Treatment Engagement Among Patients with Diabetes Treated with Insulin Glargine 300 U/mL Who Participated in the COACH Support Program

  2018cites this paper
• Concentrated insulins: History and critical reappraisal

  2018cites this paper
• Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2018cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL

  2017cites this paper
• Type 2 diabetes specialty clinic model for the accountable care organization era.

  2017cites this paper
• Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice

  2017cites this paper
• A Review of the Clinical Efficacy and Safety of Insulin Degludec and Glargine 300 U/mL in the Treatment of Diabetes Mellitus.

  2017cites this paper
• Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL: 1‐year patient‐level meta‐analysis of the EDITION clinical studies in people with type 2 diabetes

  2017cites this paper
• The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes

  2017cites this paper
• Glycaemic control and hypoglycaemia with insulin glargine 300U/mL versus insulin glargine 100U/mL in insulin-naïve people with type 2 diabetes: 12-month results from the EDITION 3 trial.

  2017cites this paper
• Novel Concentrated Insulin Delivery Devices: Developments for Safe and Simple Dose Conversions

  2017cites this paper
• Challenges and unmet needs in basal insulin therapy: lessons from the Asian experience

  2017cites this paper
• Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus

  2017cites this paper
• Hypoglycemia After Initiation of Basal Insulin in Patients with Type 2 Diabetes in the United States: Implications for Treatment Discontinuation and Healthcare Costs and Utilization

  2017cites this paper
• Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Using Combinations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist.

  2017cites this paper
• Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)

  2017cites this paper
• Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.

  2017cites this paper
• Möglichkeiten und Grenzen der aktuellen Insulintherapie

  2017cites this paper
• A Clinical Review of Concentrated Insulins for Type 1 and Type 2 Diabetes Mellitus

  2017cites this paper
• Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes

  2017cites this paper
• Glycaemic control and hypoglycaemia with insulin glargine 300 U/mL compared with glargine 100 U/mL in Japanese adults with type 2 diabetes using basal insulin plus oral anti-hyperglycaemic drugs (EDITION JP 2 randomised 12-month trial including 6-month extension).

  2017cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2017cites this paper
• Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Dovepress

  2016cites this paper
• Concepts and clinical use of ultra-long basal insulin

  2016cites this paper
• BASAL INSULIN 4.0: UPDATING YOUR CLINICAL PRACTICE WITH ULTRALONG-ACTING INSULINS AND INSULIN COMBINATION THERAPY.

  2016cites this paper
• Concentrated insulins: the new basal insulins

  2016influential citation
• Insulin glargine 300 U/mL in the management of diabetes: clinical utility and patient perspectives

  2016cites this paper
• Dynamics in insulin requirements and treatment safety.

  2016cites this paper
• A primer on concentrated insulins: what an internist should know

  2016cites this paper